Please assess the completion status of the following clinical trial:

Trial Title: Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a proven AAA of \>30 mm and \< 55 mm~2. Age between 18 and 75y (both inclusive)~3. Weight \> 50 kg~4. Mild to moderate hypertension (defined as 130 \< msSBP \< 180 or 85\< msDBP \<110), at screening and/or baseline, without current antihypertensive medication.~Exclusion Criteria:~1. Patients without an AAA, or with an AAA ≥ 55 mm, or ≤ 30 mm~2. Patients with an AAA who are eligible for surgical repair for any reason~3. Diabetes mellitus~4. Inability of the subjects to switch from all prior antihypertensive medications safely as required by the protocol and need for drugs other than study drugs at the time of baseline~5. Severe hypertension (msSBP ≥180 mmHg and/or msDBP ≥110 mmHg) at screening and/or baseline~6. Pregnant or nursing (lactating) women~7. Known or suspected contraindications, including history of allergy or hypersensitivity (such as angioedema) to DRIs, CCBs, ACEIs, statins, acetylsalicylic acid or diuretics in general (for example, to aliskiren / amlodipine / hydrochlorothiazide / statins)~8. Concomitant drugs that are strong inhibitors of CYP3A4 or P-glycoprotein inhibitors (ketoconazole, itraconazole, nefazodone, clarithromycin, ritonavir, nelfinavir, cyclosporine, verapamil, quinidine)~9. Previous or current diagnosis of heart failure (NYHA Class II-IV)~10. Second or third degree heart block without a pacemaker, or potentially life-threatening arrhythmia during the 12 months prior to screening~11. Clinically symptomatic valvular heart disease at screening visit~12. A past medical history of clinically significant ECG abnormalities~13. Confirmed serum potassium ≥5.3 mEq/L (mmol/L) at screening or baseline.~14. Impaired renal function, defined as eGFR \< 45 mL/min/1.73 m2 MDRD~15. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation~16. Participation in any clinical investigation within four (4) weeks prior to first dose or longer if required by local regulations, and for any other limitation of participation based on local regulations.~17. Patients who have undergone prior radionuclide treatment or examinations or X-ray examinations with a cumulative radiation exposure, which added to the radiation exposure of the current study, would exceed local limits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: EXPERIMENTAL): Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
- Amlodipine (Type: ACTIVE_COMPARATOR): Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).